Autoimmune Disease Diagnostics: Global Markets
The global market value for autoimmune disease diagnostics for 2013 was valued at $11.9 billion. This is expected to reach about $12.1 billion in 2014 and $13.1 billion in 2019, with a compound annual growth rate (CAGR) of 1.6% for the five-year period, 2014 to 2019.
- An overview of the global market for autoimmune disease diagnostics.
- Analyses of global market trends, with data from 2012 and 2013, estimates for 2014, and projections of CAGRs through 2019.
- Segmentation of the market by disease, by geographical location, and by gender.
- Industry analysis with focuses on customers, suppliers, competitors, new entrants, substitutes, and complements.
- Comprehensive company profiles of major players in the industry.
SCOPE OF REPORT
The report provides a thorough background of the structure of the market and outlines the chief challenges and opportunities it faces. This report estimates the global diagnostics market for autoimmune diseases. Market size for the years 2012, 2013, 2014 and 2019 is presented. In addition, market size by various segments, namely geographic regions, gender and disease phase (pre-treatment and in-treatment) is included.
Market size estimates for pre-treatment and during-treatment phases are presented. The pre-treatment and during-treatment analyses consider the complete spectrum of tests available, including autoimmune-specific tests and complementary tests such as routine blood analyses. The estimates also include ex-vivo diagnostics techniques such as X-ray and other imaging-based techniques.
Certain autoimmune disorders are more prevalent than others and form the bulk of the diseases. This report covers the market specifically for these more prevalent disorders, namely:
- Rheumatoid arthritis.
- Inflammatory bowel disease.
- Type 1 diabetes.
- Multiple sclerosis.
- Systemic lupus erythematous (SLE).
Anandi Karumbati is the BCC Research analyst for this report. She holds a degree in Pharmacy from Birla Institute of Technology and Sciences (India) and a Ph.D. in Toxicology from the University of Kentucky (U.S). She has five years of post doctoral training in genetics and biochemistry from the University of Michigan and has worked for three years at ReaMetrix Pvt Ltd., a diagnostics company in India. She is currently Lead Scientist at the Centre for Cellular and Molecular Platforms (India).